Biopharma manufacturing company Repligen Corporation (NASDAQ: RGEN) will be reporting results this Tuesday before market hours. Here’s what investors should know.
Repligen beat analysts’ revenue expectations by 4.1% last quarter, reporting revenues of $182.4 million, up 14.8% year on year. It was a strong quarter for the company, with a solid beat of analysts’ revenue estimates and full-year revenue guidance beating analysts’ expectations.
Is Repligen a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Repligen’s revenue to grow 17.4% year on year to $181.9 million, improving from the 9.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.42 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Repligen has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Repligen’s peers in the life sciences tools & services segment, some have already reported their Q3 results, giving us a hint as to what we can expect. West Pharmaceutical Services delivered year-on-year revenue growth of 7.7%, beating analysts’ expectations by 2.1%, and Medpace reported revenues up 23.7%, topping estimates by 2.7%. West Pharmaceutical Services traded up 7.5% following the results while Medpace was also up 8.9%.
Read our full analysis of West Pharmaceutical Services’s results here and Medpace’s results here.
There has been positive sentiment among investors in the life sciences tools & services segment, with share prices up 7.6% on average over the last month. Repligen is up 36.9% during the same time and is heading into earnings with an average analyst price target of $180.33 (compared to the current share price of $169.86).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
